Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Experimental and Therapeutic Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-0981 Online ISSN: 1792-1015
Journal Cover
March 2012 Volume 3 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
March 2012 Volume 3 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

CHOP and caspase 3 induction underlie glioblastoma cell death in response to endoplasmic reticulum stress

  • Authors:
    • Quincy A. Quick
    • Milton O. Faison
  • View Affiliations / Copyright

    Affiliations: Department of Biology, Southern University at New Orleans, New Orleans, LA 70126, USA, Department of Biology, Virginia State University, Petersburg, VA 23806, USA
  • Pages: 487-492
    |
    Published online on: December 19, 2011
       https://doi.org/10.3892/etm.2011.422
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:


Abstract

The unfolded protein endoplasmic reticulum stress response has emerged as a cellular physiological target to invoke tumor cell killing due to its homeostatic and cytoprotective functions. In this study, thapsigargin and tunicamycin, two endoplasmic reticulum stress inducers, were investigated for their efficacy on glioblastomas. We demonstrate that clinically relevant concentrations of thapsigargin and tunicamycin eliminate the glioblastoma cell reproductive capacity as a consequence of cell death. The mode of glioblastoma‑induced cell death was determined to be via apoptosis as supported by increased C/EBP homologous protein (CHOP) levels and caspase 3 activity, two proteins with established roles in endoplasmic reticulum stress-induced cell death. In conclusion, this study provides evidence that glioblastomas are responsive to endoplasmic reticulum stress induction as a cellular program to eradicate this tumor via programmed cell death.

Introduction

Glioblastomas are among the most chemo-resistant types of human cancers to treat clinically. The refractiveness of glioblastomas to chemotherapy treatment regimens may be attributed in part to the activation of a number of cytoprotective mechanisms in response to chemotherapeutic agents (1,2). One such cytoprotective mechanism that has emerged and received considerable attention as a contributing factor to the therapeutic resistance of a number of types of human cancer in general, and in glioblastomas in particular, is the unfolded protein endoplasmic reticulum stress response (3,4). The unfolded protein endoplasmic reticulum stress response fundamentally functions as an adaptive cellular program essential for normal cellular function and survival, that is triggered by the accumulation of unfolded proteins in the endoplasmic reticulum due to a number of stress inducers, such as hypoxia, oxidative injury, glucose deprivation and aberrant calcium levels. However, if the stress applied to the endoplasmic reticulum is excessive and exceeds its ability to maintain homeostatic control, apoptotic cell death ensues (3,4). Therefore, assessing the efficacy of agents that invoke endoplasmic reticulum stress for their utility as potential chemotherapeutic drugs that promote glioblastoma cell death should be given practical consideration. In support of this, a number of investigational studies have demonstrated the anti-tumorigenic effects of novel endoplasmic reticulum stress inducers in leukemia (5), stomach (6) and prostate cancer (7). Furthermore, recent studies have established that glucose regulated protein 78 (GRP78), an endoplasmic reticulum chaperone with anti-apoptotic properties and a significant role in the unfolded protein endoplasmic reticulum stress response signaling pathway, is overexpressed in malignant gliomas (8–10).

To this end, in the present study, we examined two endoplasmic reticulum stress inducers, thapsigargin and tunicamycin, for their anti-tumor properties on glioblastomas. Thapsigargin, an active component found in root extracts of the umbelliferous plant, Thapsia garganica, acts as a stress inducer by increasing the intracellular calcium concentration via the inhibition of calcium uptake into the endoplasmic reticulum by blocking its ATP-dependent calcium pump (11), while tunicamycin, a nucleoside antibiotic produced by several Streptomyces species, imposes cellular stress by inhibiting protein N-linked glycosylation, the first step in protein glycosylation (12). This study reveals that the endoplasmic reticulum stress inducers, thapsigargin and tunicamycin, promote glioblastoma cell death as a consequence of inducing the pro-apoptotic proteins, C/EBP homologous protein (CHOP) and caspase 3.

Materials and methods

Cells, conditions and reagents

U373 and A172 glioblastoma cells were purchased from the American Type Culture Collection (Manassas, VA, USA). All cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (Invitrogen), 2 mM L-glutamine (Invitrogen), 100 nM MEM non-essential amino acids (Invitrogen) and penicillin-streptomycin (Invitrogen) at 37°C and 5% CO2. Thapsigargin and tunicamycin were purchased from Tocris (Ellisville, MO, USA).

Crystal violet cell proliferation assay
Dose response

Cells were plated in 12-well plates, treated with 1, 5 and 10 μM thapsigargin or tunicamycin and allowed to incubate for 48 h [vehicle controls were treated with dimethyl sulfoxide (DMSO)]. The tissue culture medium was then removed, and the cell monolayer was fixed with 100% methanol for 5 min and stained with 0.5% crystal violet in 25% methanol for 10 min. The cells were then washed three times for 5 min each with distilled water to remove excess dye and allowed to dry overnight at room temperature. The incorporated dye was then solubilized in 0.1 M sodium citrate (Sigma-Aldrich, St. Louis, MO, USA) in 50% ethanol. Subsequently, 100 μl of treated and control samples were transferred to 96-well plates and optical densities were read at 540 nm using an X-mark microplate absorbance spectrophotometer (BioRad, Hercules, CA, USA).

Time course analysis. Cells were plated in 96-well plates for 24 h, treated with 1 μM thapsigargin or tunicamycin and allowed to incubate for 1, 3 and 6 days at 37°C. At the end of each time-point the cells were stained with crystal violet, solubilized with sodium citrate, and the optical densities were read as described above.

Clonogenic survival

Cells were plated for 24 h, treated with 1 μM and 250 nM thapsigargin, tunicamycin or DMSO (vehicle) and allowed to incubate at 37°C for 10–14 days. At the termination of the incubation period, cells were fixed with absolute methanol, stained with 1% crystal violet for 10 min, rinsed in tap water and allowed to dry. Colonies, consisting of ≥50 cells, were then counted to determine the surviving fraction.

Cell motility

Motility assays were conducted according to the manufacturer's instructions (Cell Biolabs Inc., San Diego, CA, USA). A cell suspension containing 0.5–1.0×106 cells/ ml was prepared in serum-free medium with the vehicle (DMSO), 1 μM thapsigargin or 1 μM tunicamycin, while 500 μl of medium containing 10% fetal bovine serum were added to the lower chamber of the migration plate. A total of 300 μl of cell suspension containing vehicle, 1 μM thapsigargin or tunicamycin was then added to the inside of each insert and allowed to incubate for 24 h at 37°C and 5% CO2. Subsequently, non-migratory cells were removed from plate inserts (according to the manufacturer's instructions) and migratory cells were counterstained with cell staining solution (Cell Biolabs Inc.).

Western blotting

Cells were plated in serum-free DMEM for 24 h, treated with 1 μM thapsigargin, 1 μM tunicamycin or the vehicle, and allowed to incubate for 24 and 48 h. The cells were then lysed in lysis buffer (pH 6.8) containing 60 mM Tris and 2% SDS. Protein concentrations were determined using the Bradford method. Subsequently, protein samples were electrophoresed in a 4–12% Tris-HCl polyacrylamide gel, transferred to nitrocellulose membranes and immunoblotted with antibodies against CHOP (Cell Signaling, Danvers, MA, USA). Protein levels were detected using a horseradish peroxidase conjugated secondary antibody and the chemiluminescence detection system (Pierce, Rockford, IL, USA).

Detection of caspase activity

Cells were plated in serum-free DMEM for 24 h, treated with 1 μM thapsigargin, 1 μM tunicamycin or the vehicle and allowed to incubate for 48 h. Cells were lysed in lysis buffer (pH 6.8) containing 60 mM Tris and 2% SDS, and protein concentrations were determined using the Bradford method. Subsequently, caspase 3 activity assays were conducted according to manufacturer's instructions using 30 μg of protein (Promega, Madison, WI, USA).

Results

Endoplasmic reticulum stress inducers impede glioblastoma cell production

Eliciting a hyper-stress response in the endoplasmic reticulum as a means of promoting anti-tumor cell behavior due to the accumulation of unfolded proteins or an unstable physiological cellular environment, such as increased intracellular calcium concentration, has been demonstrated in a variety of types of human cancer (13–17). In this study, we performed a comparative assessment of two endoplasmic reticulum stress inducers, thapsigargin and tunicamycin, with markedly different modes of stressing the endoplasmic reticulum for their anti-tumor properties on glioblastomas. Thapsigargin and tunicamycin were first examined for their effects on glioblastoma cells in dose-response experiments. These experiments revealed a dose-dependent decrease in glioblastoma cell proliferation in A172 and U373 cells exposed to increasing concentrations (1–10 μM) of thapsigargin or tunicamycin, as compared to the vehicle-treated control cells (Fig. 1). Dose response data also revealed that the inhibitory effects on A172 and U373 glioblastoma cell proliferation were more pronounced in the cells treated with 5–10 μM thapsigargin as compared to the cells treated with 5–10 μM tunicamycin. Additionally, A172 cells appeared to be more sensitive to endoplasmic reticulum stress as indicated by a 44±6 and 27±11% reduction in cell proliferation (compared to controls) when treated with 1 μM thapsigargin or tunicamycin, respectively, in comparison to the U373 cells treated with either endoplasmic reticulum stress inducer at the same concentration.

Figure 1.

Dose response of thapsigargin and tunicamycin on A172 and U373 glioblastoma cells. Vehicle-treated (DMSO) control cells (white bars); 10 μM (solid black bars); 5 μM (hatched bars); 1 μM (graybars). Data shown are representative of 3 independent experiments (means ± SE) performed in duplicate showing similar results (*p<0.05, Student's t-test). DMSO, dimethyl sulfoxide; SE, standard error.

To further examine the inhibitory effects of thapsigargin and tunicamycin on glioblastoma cell production, clonogenic survival assays that measure cellular reproductive capacity at low cell plating densities were performed by treating A172 and U373 cells with 1 μM thapsigargin or tunicamycin. This concentration was selected for its non-lethal effects on U373 cells, and showed an inhibitory concentration greater than 50 (>IC50) in A172 cells, as shown in the dose-response experiments. Clonogenic survival experiments revealed that in comparison to the vehicle-treated control cells, thapsigargin or tunicamycin completely abrogated colony formation of A172 (Fig. 2) and U373 (Fig. 3) cells.

Figure 2.

Clonogenic survival of A172 glioblastoma cells treated with endoplasmic reticulum stress inducers. (A) Vehicle control (DMSO); (B) thapsigargin (1 μM); (C) tunicamycin (1 μM). Cells shown are of a single colony stained with crystal violet from a clonogenic survival experiment. Data shown are representative of at least 3 independent experiments (means ± SE) performed in duplicate with comparable results (scale bar = 200 μm). DMSO, dimethyl sulfoxide; SE, standard error.

Figure 3.

Clonogenic survival of U373 glioblastoma cells treated with endoplasmic reticulum stress inducers. (A) Vehicle control (DMSO); (B) thapsigargin (1 μM); (C) tunicamycin (1 μM). Cells shown are of a single colony stained with crystal violet from a clonogenic survival experiment. Data shown are representative of at least 3 independent experiments (means ± SE) performed in duplicate with comparable results (scale bar = 200 μm). DMSO, dimethyl sulfoxide; SE, standard error.

In addition to clonogenic survival experiments, time-course experiments were performed as a means to determine the cellular behavior underlying the inhibition of glioblastoma cell proliferation in response to thapsigargin or tunicamycin exposure (Fig. 4). Analysis of glioblastoma cell proliferation was conducted over a 6-day period post-exposure to the vehicle, thapsigargin or tunicamycin. The most demonstrative effects of thapsigargin or tunicamycin on A172 and U373 cell production were observed on day 6, with a statistically significant (p<0.05) decrease in glioblastoma cell proliferation as compared to the vehicle-treated control cells examined at the same time-point (Fig. 4). Time course data also displayed a 28±4 and 52±4% reduction in A172 cell proliferation 6 days post-treatment with thapsigargin or tunicamycin, respectively, in comparison to A172 cell proliferation observed on day 0 (Fig. 4). A comparative assessment between these same time-points in U373 cells also revealed a decrease in cell proliferation 6 days post-treatment with either thapsigargin or tunicamycin when compared to U373 cell proliferation on day 0 (Fig. 4). Taken together, the time course data presented here suggest that the overall inhibitory effect of thapsigargin and tunicamycin was due to glioblastoma cell death. These results are similar to those from other studies on several types of human cancer that also demonstrated that thapsigargin (18–21) and tunicamycin (22–24) promoted tumor cell death.

Figure 4.

Time course analysis of glioblastoma cell proliferation post-exposure to thapsigargin or tunicamycin. Cells were exposed on day 0 to solvent (DMSO), thapsigargin (1 μM) or tunicamycin (1 μM) and monitored for a period of 6 days. The proliferation curves displayed show that, when compared to the controls, glioblastoma cell proliferation is significantly reduced when treated with thapsigargin or tunicamycin. Data shown are representative of 3 independent experiments (means ± SE) performed in duplicate displaying similar results (*p<0.05, Student's t-test). DMSO, dimethyl sulfoxide; SE, standard error.

ER stress inducers increase CHOP expression and caspase 3 activity

It is well established that the inability of the endoplasmic reticulum to activate compensatory mechanisms essential for cellular survival in response to stress will subsequently lead to apoptotic cell death (3,4). CHOP, a basic-leucine zipper (bZIP) transcription factor, and caspase 3, a cysteine protease, are pro-apoptotic proteins known to play prominent roles in endoplasmic reticulum stress-induced cell death (25,26). We therefore evaluated the protein expression levels of CHOP and caspase 3 in thapsigargin- and tunicamycin-treated glioblastoma cells. A temporal analysis using immunoblotting procedures revealed an up-regulation of CHOP protein levels at 24 and 48 h in A172 and U373 cells treated with 1 μM thapsigargin or tunicamycin (Fig. 5). Caspase 3 activity assessment displayed a 2.6- and 1.43-fold increase in caspase 3 activity at 48 h in A172 cells treated with thapsigargin or tunicamycin, respectively, while a 1.32- and 1.30-fold increase in caspase 3 activity was observed at the same time-point in U373 cells treated with thapsigargin or tunicamycin (Fig. 6). Although our observations are consistent with previous ones on colon cancer, leukemia and neuroblastomas, which also demonstrated that thapsigargin or tunicamycin invoked CHOP expression or caspase 3 activity (24,27–30), few studies have shown the induction of both of these pro-apoptotic proteins in the same tumor type in response to single exposures of endoplasmic reticulum stress inducers with different modes of action. This suggests that glioblastomas are susceptible to endoplasmic reticulum stress-induced cell death by diverse physiological stressors.

Figure 5.

Western blot analysis of CHOP protein levels in glioblastoma cells treated with thapsigargin (1 μM) or tunicamyicin (1 μM). A172 cells (lanes 1–5); U373 cells (lanes 6–10). Vehicle-treated control cells (DMSO) (lanes 1 and 6); thapsigargin treatment for 24 h (lanes 2 and 7); thapsigargin treatment for 48 h (lanes 3 and 8); tunicamycin treatment for 24 h (lanes 4 and 9); tunicamycin treatment for 48 h (lanes 5 and 10). The images shown are representative of 3 independent experiments performed in duplicate that displayed similar results. CHOP, C/EBP homologous protein; DMSO, dimethyl sulfoxide.

Figure 6.

Assessment of caspase 3 activity in A172 and U373 glioblastoma cells in response to thapsigargin (1 μM) and tunicamycin (1 μM) exposure. Caspase protein activity was measured 48 h post-exposure to thapsigargin or tunicamycin (vehicle control, white bars; thapsigargin, black bars; tunicamycin, gray bars). Data are represented as an average of 3 separate independent experiments (means ± SE). SE, standard error.

Effects of ER stress on glioblastoma cell motility

Glioblastomas are notoriously invasive tumors with high rates of recurrence, which are major factors contributing to their therapeutic refractiveness during clinical treatment (surgery, chemo- and radiotherapy) regimens. Few studies to date have investigated the role of the unfolded protein endoplasmic reticulum stress response in tumor cell motility and invasion. However, a study by Chiu et al (31) on head and neck cancers revealed that silencing the function of the endoplasmic reticulum chaperone protein, GRP78, using siRNA reduced the metastatic potential of these cancers; thus, providing evidence for a role of the unfolded protein endoplasmic reticulum stress response in the metastatic invasion of tumor cells. Therefore, in this study, we examined the effects of thapsigargin and tunicamycin on glioblastoma cell motility, a prerequisite cellular program for invasive tumor cells. In contrast to the findings by Chiu et al (31), we did not observe antagonistic effects of thapsigargin or tunicamycin on glioblastoma cell motility (Fig. 7), which is likely due to variations in the experimental approach and the differential mechanisms targeted.

Figure 7.

Motility of A172 (left) and U373 (right) glioblastoma cells treated with the endoplasmic reticulum stress inducers, thapsigargin and tunicamycin. Motility was determined with boyden chamber assays and the results are shown as micrographs of glioblastoma cells stained with crystal violet. (A and D) Vehicle (DMSO)-treated cells; (B and E) cells treated with 1 μM thapsigargin; (C and F) cells treated with 1 μM tunicamycin. The images shown are representative of 3 independent experiments performed in duplicate that displayed similar results (scale bar = 100 μm). DMSO, dimethyl sulfoxide.

Discussion

Targeting the unfolded protein endoplasmic reticulum stress response is a relatively avant-garde yet practical therapeutic approach for the treatment of human cancers. Human tumors and their microenvironment are in a continuous flux of imbalance due to the presence of abnormally folded proteins and physiological instability, relating to fluctuations in pH and ion concentration, all of which invoke stress on tumor cells. As a survival mechanism, tumor cells respond via the activation of stress responders, such as GRP78/binding immunoglobulin protein (BiP), inositol-requiring enzyme 1α (IRE1α), protein kinase RNA-like endoplasmic reticulum kinase (PERK) and activating transcription factor 6 (ATF6) that collectively underlie the unfolded protein endoplasmic reticulum stress response and confer tumor cell cytoprotection (3,4). The involvement of cytoprotective stress responders in glioblastomas has been demonstrated in a number of recent investigations that together establish that high levels of GRP78 expression correlate with increased survival and drug resistance (8–10) in these tumors. However, studies to date have failed to demonstrate that antagonizing stress responder function, particularly GRP78, promotes glioblastoma cell death.

The dichotomy of the unfolded protein endoplasmic reticulum stress response is that stress exceeding the endoplasmic reticulum's capacity to promote cell survival will consequently result in cell death. To this end, in this study, we demonstrate that two endoplasmic reticulum stress inducers, thapsigargin and tunicamycin, promote glioblastoma cell death. Our findings are consistent with those from previous studies on several human cancers that also showed that thapsigargin (prostate, breast, leukemia, and melanoma) (18–20,30,32) and tunicamycin (neuroblastoma and melanoma) induced tumor cell death (24,33).

It is well established that the mechanism affiliated with endoplasmic reticulum stress-induced cell death is the activation of the transcription factor, CHOP, a downstream pro-apoptotic component of the IRE1α, PERK and ATF6 stress responder pathways (25). Concomitantly with glioblastoma cell death, we observed a significant increase in CHOP expression in response to endoplasmic recticulum stress inducers. These findings parallel those observed by Rosati et al (22) and Oda et al (24) who also detected increased CHOP expression levels in leukemia and neuroblastoma cells, respectively, in response to thapsigargin and tunicamycin. Although effector molecules of CHOP still remain somewhat elusive, its overexpression has been shown to lead to a decrease in the pro-survival protein, Bcl-2 (34), providing evidence that the pro-apoptotic functions of CHOP are associated with mitochondria-dependent mechanisms of cell death. Our data support this premise and were substantiated by observations of increased caspase 3 activity in glioblastoma cells treated with thapsigargin or tunicamycin.

In spite of the pro-apoptotic effects of endoplasmic reticulum stress inducers on glioblastoma cell production observed in this study, thapsigargin and tunicamycin failed to impair glioblastoma cell motility. This is in contrast to experimental data by Chiu et al who demonstrated that silencing GRP78 function reduced cell motility and prevented tumor cell invasion of head and neck cancers (31). The differential cell motility responses observed in this study and by Chiu et al are likely attributed to divergent cellular and physiological mechanisms targeted in the unfolded protein endoplasmic reticulum stress response between our two studies, and further emphasizes the pleiotropic effects of the endoplasmic reticulum stress response on cell behavior.

Taken together, we provided evidence that hyper-stressing the endoplasmic reticulum, by using endoplasmic reticulum stress inducers with markedly different modes of action, is a viable approach for the promotion of killing glioblastomas. Furthermore, our study suggests that endoplasmic reticulum stress inducers exert their anti-tumorigenic effects on proliferating cells, a selective advantage for treating clinical glioblastomas which typically reside in regions of the human brain that contain dormant cells.

Acknowledgements

This work was supported by grant number P20MD002731 from the National Institute on Minority Health and Health Disparities (MOF). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Minority Health and Health Disparities or the National Institutes of Health.

References

1. 

C KrakstadM ChekenyaSurvival signaling and apoptosis resistance in glioblastomas: opportunities for targeted therapeuticsMol Cancer9135201010.1186/1476-4598-9-13520515495

2. 

D KögelS FuldaM MittelbronnTherapeutic exploitation of apoptosis and autophagy for glioblastomaAnticancer Agents Med Chem10438449201020879985

3. 

G WangZ YangK ZhangEndoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potentialAm J Transl Res26574201020182583

4. 

GC ShoreFR PapaSA OakesSignaling cell death from the endoplasmic reticulum stress responseCurr Opin Cell Biol2143149201110.1016/j.ceb.2010.11.00321146390

5. 

S LustB VanhoeckeM Van GeleJ BoelensH Van MelckebekeM KailehW Vanden BergheG HaegemanJ PhilippéM BrackeF OffnerXanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemiaAnticancer Res1037973805200919846911

6. 

X HuangZ ZhangL JiaY ZhaoX ZhangK WuEndoplasmic reticulum stress contributes to vitamin E succinate-induced apoptosis in human gastric cancer SGC-7901 cellsCancer Lett296123131201010.1016/j.canlet.2010.04.00220435408

7. 

P RavananR SanoT PritiS OgasawaraSI MatsuzawaM CuddySK SinghGS RaoP KondaiahJC ReedSynthetic triterpenoid cyano enone of methyl boswellate (CEMB) activates intrinsic, extrinsic and endoplasmic reticulum stress cell death pathways in tumor cell linesMol Cancer Ther1016351643201110.1158/1535-7163.MCT-10-0887

8. 

P PyrkoAH SchönthalF HofmanTC ChenAS LeeThe unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomasCancer Res6798099816200710.1158/0008-5472.CAN-07-062517942911

9. 

JJ VirreyD DongC StilesJB PattersonL PenM NiAH SchonthalTC ChenFM HofmanAS LeeStress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cellsMol Cancer Res612681275200810.1158/1541-7786.MCR-08-006018708359

10. 

HK LeeC XiangS CazacuS FinnissG KazimirskyN LemkeNL LehmanSA RempelT MikkelsenC BrodieGRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosisNeuro Oncol10236243200810.1215/15228517-2008-00618403493

11. 

P SabałaM CzarnyJP WoronczakJ BarańskaThapsigargin: potent inhibitor of Ca2+ transport ATP-ases of endoplasmic and sarcoplasmic reticulumActa Biochim Pol403093191993

12. 

K IsonoNucleoside antibiotics: structure, biological activity, and biosynthesisJ Antibiot (Tokyo)4117111739198810.7164/antibiotics.41.17113061990

13. 

CN HancockLH StockwinB HanRD DivelbissJH JunSV MalhotraMG HollingsheadDL NewtonA copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivoFree Radic Biol Med50110121201110.1016/j.freeradbiomed.2010.10.69620971185

14. 

SK MinSK LeeJS ParkJ LeeJY PaengSI LeeHJ LeeY KimHO PaeSK LeeEC KimEndoplasmic reticulum stress is involved in hydrogen peroxide induced apoptosis in immortalized and malignant human oral keratinocytesJ Oral Pathol Med37490498200810.1111/j.1600-0714.2008.00679.x18631371

15. 

Y WatanabeH TsuchiyaT SakabeS MatsuokaY AkechiY FujimotoK YamaneR IkedaR NishioK TerabayashiCD437 induces apoptosis in ovarian adenocarcinoma cells via ER stress signalingBiochem Biophys Res Commun366840847200810.1016/j.bbrc.2007.12.02818082618

16. 

JH JooG LiaoJB CollinsSF GrissomAM JettenFarnesol-induced apoptosis in human lung carcinoma cells is coupled to the endoplasmic reticulum stress responseCancer Res6779297936200710.1158/0008-5472.CAN-07-093117699800

17. 

A YacoubHA HamedJ AllegoodC MitchellS SpiegelMS LesniakB OgretmenR DashD SarkarWC BroaddusPERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cellsCancer Res7011201129201010.1158/0008-5472.CAN-09-404320103619

18. 

C JackischHA HahmB TombalD McCloskeyK ButashNE DavidsonSR DenmeadeDelayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cellsClin Cancer Res6284428502000

19. 

JK HuangCT ChouHT ChangSS ShuCC KuoJY TsaiWC LiaoJL WangKL LinYC LuEffect of thapsigargin on Ca2+ fluxes and viability in human prostate cancer cellsJ Recept Signal Transduct Res312472552011

20. 

DJ Vander GriendL AntonySL DalrympleY XuSB ChristensenSR DenmeadeJT IsaacsAmino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cellsMol Cancer Ther8134013492009

21. 

Y KanekoA TsukamotoThapsigargin-induced persistent intracellular calcium pool depletion and apoptosis in human hepatoma cellsCancer Lett79147155199410.1016/0304-3835(94)90253-48019972

22. 

E RosatiR SabatiniG RampinoF De FalcoM Di IanniF FalzettiK FettucciariA BartoliI ScrepantiP MarconiNovel targets for endoplasmic reticulum stress-induced apoptosis in B-CLLBlood11627132723201010.1182/blood-2010-03-27562820628148

23. 

L GirnitaM WangY XieG NilssonA DricuJ WejdeO LarssonInhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implicationsAnticancer Drug Des156772200010888037

24. 

T OdaY KosugeM ArakawaK IshigeY ItoDistinct mechanism of cell death is responsible for tunicamycin-induced ER stress in SK-N-SH and SH-SY5Y cellsNeurosci Res602939200810.1016/j.neures.2007.09.00518029041

25. 

S OyadomariM MoriRoles of CHOP/GADD153 in endoplasmic reticulum stressCell Death Differ11381389200410.1038/sj.cdd.440137314685163

26. 

I TabasD RonIntegrating the mechanisms of apoptosis induced by endoplasmic reticulum stressNat Cell Biol1318490201110.1038/ncb0311-18421364565

27. 

H YamaguchiK BhallaHG WangBax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondriaCancer Res6314831489200312670894

28. 

Y KitamuraA MiyamuraK TakataM IndenD TsuchiyaK NakamuraT TaniguchiPossible involvement of both endoplasmic reticulum-and mitochondria-dependent pathways in thapsigargin-induced apoptosis in human neuroblastoma SH-SY5Y cellsJ Pharmacol Sci92228236200310.1254/jphs.92.228

29. 

MK DahmerCaspases-2, -3, and -7 are involved in thapsigargin-induced apoptosis of SH-SY5Y neuroblastoma cellsJ Neurosci Res80576583200510.1002/jnr.2047115825194

30. 

XQ FengY YouJ XiaoP ZouThapsigargin-induced apoptosis of K562 cells and its mechanismZhongguo Shi Yan Xue Ye Xue Za Zhi142530200616584585

31. 

CC ChiuCY LinLY LeeYJ ChenTF KuoJT ChangCT LiaoHM WangTC YenCR ShenSK LiaoAJ ChengGlucose-regulated protein 78 regulates multiple malignant phenotypes in head and neck cancer and may serve as a molecular target of therapeutic interventionMol Cancer Ther727882797200810.1158/1535-7163.MCT-08-0172

32. 

LH ChenCC JiangKA KiejdaYF WangRF ThorneXD ZhangP HerseyThapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein responseCarcinogenesis2823282336200710.1093/carcin/bgm173

33. 

A DricuM CarlbergM WangO LarssonInhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosisCancer Res575435481997

34. 

KD McCulloughJL MartindaleLO KlotzTY AwNJ HolbrookGadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox stateMol Cell Biol2112491259200110.1128/MCB.21.4.1249-1259.200111158311

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Quick QA and Faison MO: CHOP and caspase 3 induction underlie glioblastoma cell death in response to endoplasmic reticulum stress. Exp Ther Med 3: 487-492, 2012.
APA
Quick, Q.A., & Faison, M.O. (2012). CHOP and caspase 3 induction underlie glioblastoma cell death in response to endoplasmic reticulum stress. Experimental and Therapeutic Medicine, 3, 487-492. https://doi.org/10.3892/etm.2011.422
MLA
Quick, Q. A., Faison, M. O."CHOP and caspase 3 induction underlie glioblastoma cell death in response to endoplasmic reticulum stress". Experimental and Therapeutic Medicine 3.3 (2012): 487-492.
Chicago
Quick, Q. A., Faison, M. O."CHOP and caspase 3 induction underlie glioblastoma cell death in response to endoplasmic reticulum stress". Experimental and Therapeutic Medicine 3, no. 3 (2012): 487-492. https://doi.org/10.3892/etm.2011.422
Copy and paste a formatted citation
x
Spandidos Publications style
Quick QA and Faison MO: CHOP and caspase 3 induction underlie glioblastoma cell death in response to endoplasmic reticulum stress. Exp Ther Med 3: 487-492, 2012.
APA
Quick, Q.A., & Faison, M.O. (2012). CHOP and caspase 3 induction underlie glioblastoma cell death in response to endoplasmic reticulum stress. Experimental and Therapeutic Medicine, 3, 487-492. https://doi.org/10.3892/etm.2011.422
MLA
Quick, Q. A., Faison, M. O."CHOP and caspase 3 induction underlie glioblastoma cell death in response to endoplasmic reticulum stress". Experimental and Therapeutic Medicine 3.3 (2012): 487-492.
Chicago
Quick, Q. A., Faison, M. O."CHOP and caspase 3 induction underlie glioblastoma cell death in response to endoplasmic reticulum stress". Experimental and Therapeutic Medicine 3, no. 3 (2012): 487-492. https://doi.org/10.3892/etm.2011.422
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team